Working Paper: NBER ID: w11949
Authors: Daron Acemoglu; David Cutler; Amy Finkelstein; Joshua Linn
Abstract: The introduction of Medicare in 1965 was the single largest change in health insurance coverage in U.S. history. Many economists and commentators have conjectured that the introduction of Medicare may have also been an important impetus for the development of new drugs that are now commonly used by the elderly and have substantially extended their life expectancy. In this paper, we investigate whether Medicare induced pharmaceutical innovations directed towards the elderly. Medicare could have played such a role only if two conditions were met. First, Medicare would have to increase drug spending by the elderly. Second, the pharmaceutical companies would have to respond to the change in market size for drugs caused by Medicare by changing the direction of their research. Our empirical work finds no evidence of a "first-stage" effect of Medicare on prescription drug expenditure by the elderly. Correspondingly, we also find no evidence of a shift in pharmaceutical innovation towards therapeutic categories most used by the elderly. On the whole, therefore, our evidence does not provide support for the hypothesis that Medicare had a major effect on the direction of pharmaceutical innovation.
Keywords: Medicare; pharmaceutical innovation; health insurance; elderly
JEL Codes: H51; I18; O33; O38; L65
Edges that are evidenced by causal inference methods are in orange, and the rest are in light blue.
| Cause | Effect |
|---|---|
| Medicare (I18) | pharmaceutical innovation (O35) |
| prescription drug expenditures among the elderly (H51) | pharmaceutical innovation (O35) |
| Medicare (I18) | prescription drug expenditures among the elderly (H51) |